Европейский союз - английский - EMA (European Medicines Agency)

glenmark arzneimittel gmbh - olanzapine - schizophrenia; bipolar disorder - psycholeptics - adultsolanzapine is indicated for the treatment of schizophrenia.olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.olanzapine is indicated for the treatment of moderate to severe manic episode. in patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

Европейский союз - английский - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - verteporfin - myopia, degenerative; macular degeneration - ophthalmologicals - visudyne is indicated for the treatment of:adults with exudative (wet) age-related macular degeneration (amd) with predominantly classic subfoveal choroidal neovascularisation (cnv) or;adults with subfoveal choroidal neovascularisation secondary to pathological myopia.

Европейский союз - английский - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - capecitabine - colonic neoplasms; breast neoplasms; colorectal neoplasms; stomach neoplasms - antineoplastic agents - xeloda is indicated for the adjuvant treatment of patients following surgery of stage iii (dukes' stage c) colon cancer.xeloda is indicated for the treatment of metastatic colorectal cancer.xeloda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.xeloda in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline. xeloda is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.

Армения - английский - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

allphamed pharbil arzneimittel gmbh - ciprofloxacin (ciprofloxacin hydrochloride) - tablets film-coated - 500mg

Ирландия - английский - HPRA (Health Products Regulatory Authority)

glenmark arzneimittel gmbh - nebivolol - tablet - 10 milligram(s) - beta blocking agents, selective; nebivolol

Европейский союз - английский - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - miglustat - gaucher disease - other alimentary tract and metabolism products - miglustat dipharma is indicated for the oral treatment of adult patients with mild to moderate type 1 gaucher disease.miglustat dipharma may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.miglustat dipharma is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with niemann-pick type c disease.

Европейский союз - английский - EMA (European Medicines Agency)

betapharm arzneimittel gmbh - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastic agents - azacitidine betapharm is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 % to 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 % to 30 % blasts and multi-lineage dysplasia, according to world health organization (who) classification,aml with > 30 % marrow blasts according to the who classification.

Армения - английский - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

allphamed pharbil arzneimittel gmbh - ciprofloxacin (ciprofloxacin hydrochloride) - tablets film-coated - 500mg

Европейский союз - английский - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - sapropterin dihydrochloride - phenylketonurias - other alimentary tract and metabolism products, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment.sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.